Infliximab associated with lower likelihood of COVID-19 antibodiesPeople with COVID-19 infections who also used the inflammatory bowel disease (IBD) drug infliximab had significantly fewer detectable antibodies than those who used vedolizumab, which treats IBD without the immune suppression, according to a study yesterday in Gut.Dubbed CLARITY (ImpaCt of bioLogic therApy on saRs-cov-2 Infection and immuniTY), the study looked at 6,935 patients ages 5 and above with IBD from 92 UK hospitals from Sep 22 to Dec 23, 2020, and researchers plan to follow them up to 40 weeks thereafter.
About two thirds (67.6%) of the cohort took infliximab, while the remainder took vedolizumab. Patients' median age was 39 years.In both general seroprevalence